New weight loss drugs aim to save muscle
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate additional health benefits beyond the numbers on a scale to get approved.
Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.
Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...
Veru Inc (NASDAQ:VERU) is set to release its Q1 2025 earnings on Feb 13, 2025. The consensus estimate for Q1 2025 revenue is ...
Veru Inc. (NASDAQ:VERU – Get Free Report) was the recipient of a large increase in short interest in the month of January.As of January 31st, there was short interest totalling 14,620,000 shares ...
Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback